Psyched Wellness Completes Maximum Tolerated Dosage Study For Amanita Muscaria Extract AME-1

Psyched Wellness (CSE: PSYC) this morning issued a brief press release related to the ongoing pre-clinical trial of its muscimol extract, referred to as AME-1. The firm has received the results from its maximum tolerated dosage study, which was conducted through that of KGK Science.

The study is the first set of toxicology assessments being conducted on the Amanita Muscaria extract. The study for maximum tolerated dosage was required as part of the pre-clinical process, which will now see the company conduct studies focused on the oral toxicity of the product.

Two studies are to be conducted for the next phase of the development, with the firm to conduct both a 14 day and a 90 day oral toxicity study. Once completed, the data will be used to determine effective and safe dosages for human consumption of the extract.

“I am pleased to share the positive results from the individual studies that our CRO is conducting in the pre clinical study on our behalf for AME 1. Today’s results pushes us one step closer to our goal of applying to the FDA for a New Dietary Ingredient and to Health Canada for a Natural Health Product Number.”

Jeff Stevens, CEO of Psyched Wellness

Psyched Wellness last traded at $0.50 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Psyched Wellness Raises $6.6 Million In Bought Deal Financing

Psyched Wellness (CSE: PSYC) has closed its previously announced private placement. The company managed to...

Wednesday, February 17, 2021, 11:38:02 AM

Psychedelics: Sector Tailwinds To Come – The Daily Dive feat Psyched Wellness CEO Jeff Stevens

Starting off the short Canadian trading week this week on the Daily Dive is that...

Tuesday, May 25, 2021, 01:30:00 PM

Psyched Wellness Commences 90-Day Toxicity Study Of AME-1

Psyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom...

Monday, June 28, 2021, 08:55:03 AM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM

Psyched Wellness Files Patent Application For Proprietary AME-1 Extraction Process

Psyched Wellness (CSE: PSYC) has begun the process of protecting its intellectual property. The firm...

Wednesday, March 17, 2021, 07:32:20 AM